HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma Published in Frontiers in Drug Discovery

HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL
PRINCETON, N.J., Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on...

Related Keywords

Brian Poligone ,Richard Straube ,Prnewswire Soligenix Inc ,Rochester Skin Lymphoma Medical Group ,Nasdaq ,Us Development ,National Institute Of Allergy ,Defense Threat Reduction Agency ,Us Congress ,Soligenix Inc ,Linkedin ,Our Public Health Solutions ,European Medicines Agency ,Development Authority ,Twitter ,Biomedical Advanced Research ,Exchange Commission ,Senior Vice President ,Chief Medical Officer ,About Cutaneoust Cell Lymphoma ,Public Health Solutions ,National Institute ,Infectious Diseases ,Project Bioshield ,Priority Review Voucher ,Markets ,